At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 26 enrolled
Drug / intervention
ASP2151 400mg + 100mg ciclosporin +1 moredrug
Likely dose
ASP2151 400mg + 100mg ciclosporinfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-centre, Open-label, Randomised, Cross-over, Drug-drug Interaction Study to Investigate the Effect of Repeated Oral Doses of Ciclosporin on the Single-dose Pharmacokinetics of nASP2151 in Healthy Mean
In Brief
A Phase 1 clinical trial evaluating ASP2151 400mg + 100mg ciclosporin and ASP2151 1200mg + 100mg ciclosporin for Healthy. Completed, enrolled 26 participants across 1 site.
Detailed Summary
ASP2151 is an experimental treatment for herpes. Patients undergoing organ and tissue transplantation may be prescribed ciclosporin to suppress their immune system to give the transplant an increased chance of not being rejected. A patient with a compromised immune system is more susceptible to infections such as herpes, which will require treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartOct 2014
First PostedOct 2014
Primary CompletionJan 2015
TodayJul 2026
First PostedOct 31, 2014
Enrollment StartOct 1, 2014
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11.7 years ago
Interventions
ASP2151 400mg + 100mg ciclosporindrug
ASP2151 1200mg + 100mg ciclosporindrug